GCM
TVRD

Graham Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Graham Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-532
Closed -$54.2K – 1329
2023
Q2 		$54.2K Buy
+532
New +$73.3K ﹤0.01% 915

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Graham Capital Management's TVRD Position: Q3 2023 in Review

Graham Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 532 shares — an estimated $54.2K sold.

Graham Capital Management first reported a position in TVRD in Q2 2023 and held it in 1 quarter. The position peaked at $54.2K in Q2 2023. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • Graham Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Graham Capital Management sold 532 Tvardi Therapeutics shares in Q3 2023, an estimated $54.2K.
  • Graham Capital Management first reported a position in Tvardi Therapeutics in Q2 2023 and held it in 1 quarter.
  • Graham Capital Management's Tvardi Therapeutics position peaked at $54.2K in Q2 2023.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Graham Capital Management's 13F filing for Q3 2023, filed 22 Nov 2023.